Stock Track | iRadimed Soars 5.20% Intraday on Strong Q1 Earnings Beat and Successful New Product Launch

Stock Track05-02

iRadimed Corporation's stock soared 5.20% during intraday trading on Friday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations.

The MRI-compatible medical device maker reported quarterly adjusted earnings of $0.49 per share, beating the consensus estimate of $0.45. Revenue for the quarter rose 13% year-over-year to $22 million, also surpassing the $21.3 million analysts had forecast. The company attributed this strong growth primarily to the successful commercial launch of its next-generation 3870 MRI-compatible IV infusion pump, which has generated strong early order activity with larger order sizes than the prior-generation platform.

Adding to investor confidence, iRadimed reaffirmed its full-year 2026 guidance, expecting revenue of $91 million to $96 million and adjusted earnings per share of $2.06 to $2.21. The company also declared a regular quarterly cash dividend of $0.20 per share. The combination of an earnings beat, robust revenue growth driven by a new product, and maintained positive outlook provided the catalyst for the stock's significant intraday gain.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1163995754?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-02 03:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163995754","market":"hk","top_or_hot":-1,"title":"Stock Track | iRadimed Soars 5.20% Intraday on Strong Q1 Earnings Beat and Successful New Product Launch","media":"Stock Track","content":"<p>iRadimed Corporation's stock soared 5.20% during intraday trading on Friday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations.</p><p>The MRI-compatible medical device maker reported quarterly adjusted earnings of $0.49 per share, beating the consensus estimate of $0.45. Revenue for the quarter rose 13% year-over-year to $22 million, also surpassing the $21.3 million analysts had forecast. The company attributed this strong growth primarily to the successful commercial launch of its next-generation 3870 MRI-compatible IV infusion pump, which has generated strong early order activity with larger order sizes than the prior-generation platform.</p><p>Adding to investor confidence, iRadimed reaffirmed its full-year 2026 guidance, expecting revenue of $91 million to $96 million and adjusted earnings per share of $2.06 to $2.21. The company also declared a regular quarterly cash dividend of $0.20 per share. The combination of an earnings beat, robust revenue growth driven by a new product, and maintained positive outlook provided the catalyst for the stock's significant intraday gain.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | iRadimed Soars 5.20% Intraday on Strong Q1 Earnings Beat and Successful New Product Launch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | iRadimed Soars 5.20% Intraday on Strong Q1 Earnings Beat and Successful New Product Launch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-02 03:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>iRadimed Corporation's stock soared 5.20% during intraday trading on Friday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations.</p><p>The MRI-compatible medical device maker reported quarterly adjusted earnings of $0.49 per share, beating the consensus estimate of $0.45. Revenue for the quarter rose 13% year-over-year to $22 million, also surpassing the $21.3 million analysts had forecast. The company attributed this strong growth primarily to the successful commercial launch of its next-generation 3870 MRI-compatible IV infusion pump, which has generated strong early order activity with larger order sizes than the prior-generation platform.</p><p>Adding to investor confidence, iRadimed reaffirmed its full-year 2026 guidance, expecting revenue of $91 million to $96 million and adjusted earnings per share of $2.06 to $2.21. The company also declared a regular quarterly cash dividend of $0.20 per share. The combination of an earnings beat, robust revenue growth driven by a new product, and maintained positive outlook provided the catalyst for the stock's significant intraday gain.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IRMD","symbol_name":"iRadimed Corporation","start_time":0,"source_url":"","article_id":"1163995754","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163995754","pubTimestamp":1777663903,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"iRadimed Corporation's stock soared 5.20% during intraday trading on Friday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IRMD":"iRadimed Corporation"},"translate_title":"个股追踪|iRadimed盘中大涨5.20%，因Q1盈利强劲且新产品推出成功","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRMD":1},"content_text":"iRadimed Corporation's stock soared 5.20% during intraday trading on Friday, following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations.The MRI-compatible medical device maker reported quarterly adjusted earnings of $0.49 per share, beating the consensus estimate of $0.45. Revenue for the quarter rose 13% year-over-year to $22 million, also surpassing the $21.3 million analysts had forecast. The company attributed this strong growth primarily to the successful commercial launch of its next-generation 3870 MRI-compatible IV infusion pump, which has generated strong early order activity with larger order sizes than the prior-generation platform.Adding to investor confidence, iRadimed reaffirmed its full-year 2026 guidance, expecting revenue of $91 million to $96 million and adjusted earnings per share of $2.06 to $2.21. The company also declared a regular quarterly cash dividend of $0.20 per share. The combination of an earnings beat, robust revenue growth driven by a new product, and maintained positive outlook provided the catalyst for the stock's significant intraday gain.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1163995754","isCrawlerRequest":true}